These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31545228)

  • 1. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
    Fu W; Hong Z; You X; Din J; Chen B; Zhao B; Yuan G; Li Q
    Biomed Pharmacother; 2019 Oct; 118():109374. PubMed ID: 31545228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zhoushi Qi Ling decoction represses docetaxel resistance and glycolysis of castration-resistant prostate cancer via regulation of SNHG10/miR-1271-5p/TRIM66 axis.
    Cao H; Wang D; Sun P; Chen L; Feng Y; Gao R
    Aging (Albany NY); 2021 Oct; 13(19):23096-23107. PubMed ID: 34613933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
    Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
    J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p.
    Arai T; Kojima S; Yamada Y; Sugawara S; Kato M; Yamazaki K; Naya Y; Ichikawa T; Seki N
    Mol Oncol; 2019 Feb; 13(2):322-337. PubMed ID: 30444038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Codelivery of miR-4638-5p and Docetaxel Based on Redox-Sensitive Polypeptide Micelles as an Improved Strategy for the Treatment of Castration-Resistant Prostate Cancer.
    Jiang W; Gao Y; Wang Z; Gong C; Hu C; Ding X; Qiang L; Gao S; Ren F
    Mol Pharm; 2019 Jan; 16(1):437-447. PubMed ID: 30452268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
    Zedan AH; Osther PJS; Assenholt J; Madsen JS; Hansen TF
    Sci Rep; 2020 Jan; 10(1):227. PubMed ID: 31937854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer.
    Chen F; Wu S; Kuang N; Zeng Y; Li M; Xu C
    FEBS J; 2024 Jul; 291(14):3249-3266. PubMed ID: 38712529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
    Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
    Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
    Qiu X; Wang W; Li B; Cheng B; Lin K; Bai J; Li H; Yang G
    BMC Cancer; 2019 Jan; 19(1):27. PubMed ID: 30621625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-144-3p inhibits cell proliferation and promotes apoptosis in castration-resistant prostate cancer by targeting CEP55.
    You B; Zhang KC
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7660-7670. PubMed ID: 30536308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.
    Wang Y; Shao N; Mao X; Zhu M; Fan W; Shen Z; Xiao R; Wang C; Bao W; Xu X; Yang C; Dong J; Yu D; Wu Y; Zhu C; Wen L; Lu X; Lu YJ; Feng N
    Oncotarget; 2016 Jul; 7(30):47444-47464. PubMed ID: 27329728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
    Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
    Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
    Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 17. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Tinay I; Tan M; Gui B; Werner L; Kibel AS; Jia L
    Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC.
    Arai T; Okato A; Yamada Y; Sugawara S; Kurozumi A; Kojima S; Yamazaki K; Naya Y; Ichikawa T; Seki N
    Cancer Med; 2018 May; 7(5):1988-2002. PubMed ID: 29608247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.